KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.26−0.17 (-4.96%)
Close on Nov 18, 2026Market cap $63.05MP/E –Yield –
Kala Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kala Bio's operating income for the twelve months ending Jun 30, 2026 was -$20.99M. For fiscal 2025 it was -$39.16M. The highest annual figure on record is -$15.95M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.16M | – |
| FY2024 | Dec 31, 2024 | -$40.98M | – |
| FY2023 | Dec 31, 2023 | -$39.66M | – |
| FY2022 | Dec 31, 2022 | -$81.71M | – |
| FY2021 | Dec 31, 2021 | -$130.25M | – |
| FY2020 | Dec 31, 2020 | -$96.23M | – |
| FY2019 | Dec 31, 2019 | -$88.22M | – |
| FY2018 | Dec 31, 2018 | -$64.72M | – |
| FY2017 | Dec 31, 2017 | -$39.88M | – |
| FY2016 | Dec 31, 2016 | -$32.67M | – |
| FY2015 | Dec 31, 2015 | -$15.95M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.72M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.80M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.67M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.93M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.25M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$30.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$46.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.05M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.31M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.98M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.84M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.13M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$22.41M | – |
| Q1 FY2019 | Mar 31, 2019 | -$24.05M | – |
| Q4 FY2018 | Dec 31, 2018 | -$23.57M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.50M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.52M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.14M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.14M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.53M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.63M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.57M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.20M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.75M | – |
See a number that looks wrong?